SUMMARY Somatostatin-like immunoreactivity is reduced in the cerebrospinal fluid in depression and this is presumed to reflect alterations in cerebral somatostatinergic systems. We have examined this hypothesis by measuring this immunoreactivity and somatostatin receptors in post-mortem cortical tissue from depressed patients and control subjects. There was no significant difference in the temporal and occipital cortex in somatostatin-like immunoreactivity or in somatostatin receptor affinity and binding capacity between depressed and control groups. It is concluded that there may not be an alteration of cortical somatostatin function in depression.
Somatostatin is present in both the central nervous system and peripheral tissues. It has a wide range of activities, inhibiting the secretion of many hormones, including growth hormone, and functioning as a neurotransmitter or neuromodulator.' These effects have led to studies on the involvement of somatostatin in psychiatric illnesses. Somatostatin concentrations in cerebrospinal fluid (CSF) have been reported to be reduced in depression.2`5 This finding is not, however, specific to depression, as reduced levels have also been noted in anorexia nervosa, schizophrenia and senile dementia.2 5 CSF somatostatin is considered to derive from brain tissue, with contributions from a variety of regions (although the relative importance of different regions has not been established3). Reduced CSF concentrations of somatostatin may be the result of reduced numbers of cerebral somatostatin-containing neurons, reduced release or an increased rate of elimination of somatostatin.
We have investigated somatostatin-like immunoreactivity (SLI) and somatostatin receptors in two cortical regions to establish whether there are changes in this system in depression.
Accepted 23 December 1987 Methods Subjects Depressed subjects had died of coincident physical illness while inpatients at a psychiatric hospital. A detailed description of subject selection is given by McKeith et al.6 Diagnosis was made using DSM III criteria for major depressive episode.' Nine subjects were studied (six female, three male). One subject was in the depressed phase of a bipolar affective illness. In seven of these subjects there was clinical evidence of major depression within 2 weeks before death, the other two had depressed mood during this time. Seven subjects were sub-classified as having melancholia, three of these with psychotic features. Mean age was 73, 7 yr (mean, SD; range 63-84). Time interval between death and freezing of tissue (post-mortem delay) was 5-45 h (26, 13 h; mean, SD). Subjects died of natural causes, principally from vascular disease. Two subjects were drug-free (for at least a month) at the time of death, one subject was taking benzodiazepines and the remainder were taking antidepressants. A global assessment of cognitive functioning (37 item mental test score8) was available in most cases and was not in the range suggestive of dementia.
Control subjects-had died in hospital from natural causes, principally vascular disease. Case notes were examined and subjects with a history of psychiatric illness or psychotropic medication were excluded. Seven subjects were studied (six female, one male; age 77, 6 yr; mean, SD). Post-mortem delay was 3-44 h ( 19, 26 h; mean, SD).
Brain dissection
The brain was removed from the skull, the left hemisphere was coronally sliced and the sections were sealed in poly-thene, snap-frozen in arcton and stored at -70'C. Cortical grey matter was sub-dissected from the coronal slices at -l10C. 
